Suchergebnisse - "Belada, David"

PubPharm (35)

1

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL : the phase 1b First-MIND study

enthalten in: Blood | 2023

von Belada, D. | Kopeckova, K. | Bergua Burgues, J. | +13

CommentIn: Blood. 2023 Oct 19;142(16):1331-1332. - PMID 37856095

2

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

enthalten in: European journal of haematology | 2022

von Vodicka, P. | Benesova, K. | Janikova, A. | +10

3

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

enthalten in: The New England journal of medicine | 2022

von Wang, M. | Jurczak, W. | Jerkeman, M. | +129

CommentIn: Nat Rev Clin Oncol. 2022 Aug;19(8):494. - PMID 35750854

4

Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) : long-term results of project Q-lite by the Czech CLL Study Group

enthalten in: British journal of haematology | 2021

von Smolej, L. | Brychtová, Y. | Cmunt, E. | +12

5

ROBUST : A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Nowakowski, G. | Chiappella, A. | Gascoyne, R. | +27

CommentIn: J Clin Oncol. 2021 Apr 20;39(12):1314-1316. - PMID 33621123

6

Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia

enthalten in: European journal of clinical investigation | 2021

von Šimkovič, M. | Vodárek, P. | Motyčková, M. | +10

7

The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma : analysis from the Czech Lymphoma Study Group database (NIHIL)

enthalten in: Annals of hematology | 2020

von Janikova, A. | Michalka, J. | Bortlicek, Z. | +13

8

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

enthalten in: Leukemia | 2020

von Pott, C. | Sehn, L. | Belada, D. | +11

9

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation : a phase 3, randomized, multicentre trial (PIX306)

enthalten in: British journal of haematology | 2020

von Pettengell, R. | Długosz-Danecka, M. | Andorsky, D. | +8

CommentIn: Br J Haematol. 2020 Jan;188(2):202-204. - PMID 31680237

10

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma : Long-Term Results of the PRIMA Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Bachy, E. | Seymour, J. | Feugier, P. | +28

CommentIn: J Clin Oncol. 2020 Feb 10;38(5):522. - PMID 31804862